Disintegrants for solid oral dosage forms
Peer-reviewed journal articles and scientific presentations describing the use of GLYCOLYS® sodium starch glycolate and SOLUTAB® croscarmellose sodium range as disintegrants in solid oral dosage forms
|
Study Reference |
Related Roquette excipient(s) |
Summary of results regarding Roquette excipient(s) performances |
|---|---|---|
|
An easy-to-use approach for determining the disintegration ability of disintegrants by analysis of available surface area |
GLYCOLYS® (sodium starch glycolate) |
When sodium starch glycolate was mixed with ethenzamide (ETZ) granules, faster dissolution of ETZ from tablets was observed as sodium starch glycolate concentration increased from 1.0 % to 5.0 %. Dissolution of tablets containing 1.0 % sodium starch glycolate was also significantly faster than tablets containing no disintegrants. Sodium starch glycolate also showed good water absorption (Rw) and a fast water absorption rate, which peaked at 10 min. |
|
Transfer from High‐Shear Batch to Continuous Twin Screw Wet Granulation: A Case Study in Understanding the Relationship Between Process Parameters and Product Quality Attributes |
GLYCOLYS® (sodium starch glycolate) |
Sodium starch glycolate was used in the formulation as a disintegrant (7.5 %, w/w) for continuous twin screw wet granulation, together with an active pharmaceutical ingredient, microcrystalline cellulose, mannitol, hydroxypropyl cellulose, pH modifier, lubricant and water. |
|
Tailored granule properties using 3D printed screw geometries in twin screw granulation
|
GLYCOLYS® (sodium starch glycolate) |
Sodium starch glycolate (5.1 %, w/w) was used as disintegrant in the formulations for continuous twin screw wet granulation, together with an active pharmaceutical ingredient, mannitol, microcrystalline cellulose and hydroxypropyl cellulose. |
|
Liquisolid Tablet Formulation as a Tool to Improve the Dissolution of Olmesartan Medoxomil |
GLYCOLYS® (sodium starch glycolate) |
Each liquisolid tablet formulation used in the study included 5 %, w/w sodium starch glycolate as superdisintegrant. The study demonstrated that an optimized formulation using the liquisolid method successfully improved dissolution rate of poorly soluble drug olmesartan medoxomil. |
|
Structure-Properties Relationship in the Evaluation of Alginic Acid Functionality for Tableting |
GLYCOLYS® (sodium starch glycolate) |
Sodium starch glycolate was used as one of the reference commercial disintegrants to benchmark the functionality of alginic acid as a disintegrating agent. All disintegrants were used at 5 %, w/w of the total formulation, with the filler being either microcrystalline cellulose or lactose. Disintegration time of tablets with sodium starch glycolate were comparable to tablets with crospovidone, or alginic acid. |
|
Dissolution rate enhancement of piroxicam by ordered mixing |
GLYCOLYS® LV (sodium starch glycolate) |
Ordered mixture formulations with compositions of sodium starch glycolate (8 %, w/w), a water-soluble filler such as mannitol or lactose, sodium lauryl sulfate and the active pharmaceutical ingredient, piroxicam, were successfully demonstrated to improve the dissolution rate of piroxicam. |
|
Surface dissolution UV imaging for characterization of superdisintegrants and their impact on drug dissolution |
GLYCOLYS® LV (sodium starch glycolate) |
Pronounced dissolution enhancement was observed by using low viscosity sodium starch glycolate, especially for poorly soluble active pharmaceutical ingredients like carbamazepine. |
|
Physicochemical characterization of dipeptidyl peptidase-4 inhibitor alogliptin in physical mixtures with excipients
|
SOLUTAB® (croscarmellose sodium) |
Binary formulations of alogliptin (ALG) and each excipient in a 1:1 (w/w) proportion were used to investigate compatibility in this study. ALG was found to be compatible with croscarmellose sodium. |
|
Solid-state compatibility studies of a drug without melting point |
SOLUTAB® (croscarmellose sodium) |
Binary formulations of omeprazole sodium (OMS) and excipients in a 1:1 ratio were used. OMS was found to be compatible with croscarmellose sodium. |
|
A single-dose, randomized, cross-over, two-way, open-label study for comparing the absorption of boswellic acids and its lecithin formulation
|
SOLUTAB® (croscarmellose sodium) |
Croscarmellose sodium was used in the formulation delivered as hard gelatin capsules at a quantity of 9.0 mg, together with Boswellia extract (BE)/lecithin formulation (CSP), corn starch and pregelatinized starch, silicon dioxide, magnesium stearate and talc. |
|
Application of thermal analysis in study of binary mixtures with metformin |
GLYCOLYS® Low Solvent (sodium starch glycolate) |
Sodium starch glycolate and croscarmellose sodium were found to be compatible with metformin using thermogravimetric studies, differential thermal analysis and differential scanning calorimetry techniques. |
|
Functional assessment of four types of disintegrants and their effect on the spironolactone release properties |
GLYCOLYS® Low Solvent (sodium starch glycolate) |
Sodium starch glycolate (SSG) was found to have the largest water uptake ability. Its ability to swell decreased when placed in acid media. SSG presented a large water sorption ratio due to its high ability to draw and retain water leading to a size increase. Compact disintegration times of SSG were virtually not affected by the presence of lubricant and media pH. |
|
Design and optimization of a child-friendly dispersible tablet containing isoniazid, pyrazinamide, and rifampicin for treating tuberculosis in pediatrics |
GLYCOLYS® Low Solvent (sodium starch glycolate) |
Tablets developed with 9 %, w/w of sodium starch glycolate and a compression force of 16 kN disintegrated in less than 3 min and showed a friability below 1 % when 15 mm punches were used. |
|
Controlled release of oral tetrahydrocurcumin from a novel self-emulsifying floating drug delivery system (SEFDDS) |
GLYCOLYS® Low Solvent (sodium starch glycolate) |
Higher concentrations of sodium starch glycolate resulted in rapid uptake of water, followed by rapid and enormous swelling which resulted in easy pellet disintegration. Sodium starch glycolate in the range of 0.8 – 1.6 %, w/w resulted in better controlled drug release and gradually increased the tetrahydrocurcumin release to nearly 80% within 8 h. |
|
Influence of the Superdisintegrants in Nifedipine Release from Osmotic Push-Pull Tablets |
GLYCOLYS® Low Solvent (sodium starch glycolate) |
Sodium starch glycolate was found to have the greatest drug release rate compared to crospovidone and croscarmellose sodium when used in the formulation of push-pull tablets containing Nifedipine as a model drug. |
® Registered trademark(s) of Roquette Frères